我司将于2015.2.4（周三）和ReproCELL公司子品牌Stemgent合作举办“mRNA重编程技术”网络研讨会，本次研讨会主要介绍：
1. mRNA重编程技术研究的优势 2. mRNA重编程技术与其他重编程技术的比较
如果您对mRNA重编程技术有任何疑问，请在注册后提交。 请各位IPS/ES研究人员，不要错过了解这项的先进技术的机会。 |
讲座时间
Date: Wed, Feb. 4th , 2015 Time: Boston: 8:00PM
The panel will be moderated by Brad Hamilton, Director of Research & Development, Stemgent. Brad Hamilton received his B.S. in Biology from James Madison University and his M.S. in Biotechnology from the University of Tennessee-Knoxville and has seventeen years of research experience in both industry and academic labs. During that time, Mr. Hamilton has worked at Upstate Biotechnology and Millipore, leading R&D groups in the development of RNAi and cell signaling reagents. In addition, his time spent in academic research has focused on assay development for neurodegenerative disorders. Brad is currently Director of Research and Development for Stemgent’s stem cell focused programs, including the coordination of external academic and commercial collaborations and technology evaluations. We hope to meet you at the webinar on Feb. 4th, 2015.
Stemgent RNA 体细胞重编程技术——快速、安全、高效、无基因组整合风险、无外源基因印迹的重编程技术
Stemgent RNA体细胞重编程技术可将正常细胞和疾病特异性细胞重新编程为人诱导多能干细胞，并提供两种重编程方式选择 ：（1）mRNA重编程方式（需要饲养层细胞）；（2） MicroRNA增强型-mRNA 重编程方式（无需饲养层细胞）。The microRNA Booster Kit 包括microRNA重编程试剂和B18R重组蛋白。TheStemgent® MicroRNA-Enhanced mRNA Reprogramming System改进了第一代mRNA重编程技术，更迅速更高效，更适用于难以重编程的细胞类型，甚至可以对iPS重编程的难题——血细胞重编程进行有效解决。产品联用得到原代iPS细胞系仅需8天，并使每块well的mRNA使用量降低35%-45%。 Stemgent-AsterandmRNA Reprogramming MethodStemgent-AsterandEnhanced microRNAmRNA Reprogramming MethodReprogramming efficiency>1%>1%Fast Reprogramming KineticsYesYesSomatic Cell → iPS Cell3 weeks2 weeksRisk of insertional mutagenesisNoneNoneScreening for Viral ClearanceNoneNoneScreening for DNA vector retention and/or integrationNoneNoneBio-containment issues associated with viral applicationsNoneNone# of wells per kit(6 well plate format)49-10(35%-45% per well cost reduction)Reprogramming SubstrateFibroblast feeder layerExtracellular MatrixCaptures hard-to reprogram and refractory cell types—YesSimple, user friendly protocol (overnight transfections)—Yes |
| 免责声明 |
|
1. 本公司密切关注本网站发布的内容，但不保证发布内容的准确性、完整性、可靠性和最新性等。 2. 本公司不保证使用本网站期间不会出现故障或计算机病毒污染的风险。 3. 无论何种原因，使用本网站时给用户或第三方造成的任何不利或损害，本公司概不负责。此外，对于用户与其他用户或第三方之间因本网站发生的任何交易、通讯 3. 或纠纷，本公司概不负责。 4. 本网站可提供的所有产品和服务均不得用于人体或动物的临床诊断或治疗，仅可用于科研等非医疗目的。如任何用户将本网站提供的产品和服务用于临床诊断或治 4. 疗，以及其他特定的用途或行为，本公司概不保证其安全性和有效性，并且不负任何相关的法律责任。 |
